Back to Search Start Over

Long-Term Outcomes of a Large Cohort of Patients with Eales' Disease.

Authors :
Biswas J
K R R
Pal B
Gondhale HP
Kharel Sitaula R
Source :
Ocular immunology and inflammation [Ocul Immunol Inflamm] 2018; Vol. 26 (6), pp. 870-876. Date of Electronic Publication: 2017 Apr 27.
Publication Year :
2018

Abstract

Purpose: To analyze the long-term visual outcomes of Eales' patients.<br />Methods: A retrospective review of Eales' patients diagnosed between 1985 and 1995 with >10 years follow-up done.<br />Results: We included 500 patients (898 eyes) with mean follow-up duration of 15.8 years (10-25 years), and 81% patients had bilateral disease. Patients using oral steroid during acute stage disease had significantly better visual outcome at the final visit [0.42 logMar(6/18) ± 0.723 logMar(6/30)] compared to patients who did not receive oral steroids [(0.5907 logMar(6/24) ± 0.945 logMar(6/48)] (p = 0.004). Patients who received laser therapy had significantly better visual outcome at the final visit [(0.415 logMar(6/18) ± 0.66 logMar(6/30)] compared to those who did not undergo laser treatment [(0.9237 logMar(6/48) ± 1.31 logMar(6/120)] (p < 0.001). Poor presenting visual acuity and late stage of presentation were associated with poor visual outcome. Fifty-two percent of eyes had <5 recurrences over 10 years.<br />Conclusion: Eales' disease is a bilateral recurrent retinal vasculitis disorder and timely treatment with steroid and/or laser photocoagulation result in better visual outcomes.

Details

Language :
English
ISSN :
1744-5078
Volume :
26
Issue :
6
Database :
MEDLINE
Journal :
Ocular immunology and inflammation
Publication Type :
Academic Journal
Accession number :
28448727
Full Text :
https://doi.org/10.1080/09273948.2017.1298817